Skip to main content

Published locations for FDA alert: ‘Substantial’ hypocalcemia risk with denosumab use in dialysis patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA alert: ‘Substantial’ hypocalcemia risk with denosumab use in dialysis patients

User login

  • Reset your password
  • /content/fda-alert-substantial-hypocalcemia-risk-denosumab-use-dialysis-patients
  • /clinicianreviews/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use
  • /familypracticenews/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use
  • /internalmedicinenews/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab
  • /obgynnews/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use-dialysis
  • /rheumatologynews/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use
  • /clinicalendocrinologynews/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk
  • /obgyn/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use-dialysis
  • /endocrinology/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use
  • /rheumatology/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use
  • /internalmedicine/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use
  • /familymedicine/article/259759/osteoporosis/fda-alert-substantial-hypocalcemia-risk-denosumab-use